Antti D - Herantis Pharma CEO COO

All Insiders . Finland . 
Stock . Herantis Pharma Oyj . Stakeholders . Insider . Antti D
HRTIS Stock  EUR 1.64  0.01  0.61%   

Insider

Antti D is CEO COO of Herantis Pharma Oyj
Age 48
Phone358 9222 1195
Webhttps://www.herantis.com

Herantis Pharma Management Efficiency

The company has return on total asset (ROA) of (0.6005) % which means that it has lost $0.6005 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.3662) %, meaning that it generated substantial loss on money invested by shareholders. Herantis Pharma's management efficiency ratios could be used to measure how well Herantis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Herantis Pharma Oyj has accumulated 6.29 M in total debt with debt to equity ratio (D/E) of 0.95, which is about average as compared to similar companies. Herantis Pharma Oyj has a current ratio of 1.51, which is within standard range for the sector. Debt can assist Herantis Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Herantis Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Herantis Pharma Oyj sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Herantis to invest in growth at high rates of return. When we think about Herantis Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Erkki KariKoskinenFortum Oyj
N/A
Rainer KunzHarvia Oyj
59
Ensio VisnenFortum Oyj
N/A
Marjo NurmiKamux Suomi Oy
48
Petri LLMSampo Oyj A
53
Petter MScQt Group Oyj
49
Mika LLMQt Group Oyj
53
Marko MBAQt Group Oyj
51
Katja MBAQt Group Oyj
50
Nora LLMFortum Oyj
50
Maria SilanderSampo Oyj A
N/A
Eveliina MScFortum Oyj
40
Ingela MFortum Oyj
57
Marko MScKamux Suomi Oy
51
Timo HarviaHarvia Oyj
45
Juha MQt Group Oyj
60
Paivi MScHarvia Oyj
47
Jouni LintunenQt Group Oyj
52
Katariina HietarantaKamux Suomi Oy
55
Mika SuojaHarvia Oyj
48
Milla KrpnenKamux Suomi Oy
N/A
Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. The company was founded in 2008 and is based in Espoo, Finland. Herantis Pharma operates under Pharmaceuticals And Biosciences classification in Finland and is traded on Helsinki Exchange. It employs 13 people. Herantis Pharma Oyj (HRTIS) is traded on Helsinki Exchange in Finland and employs 13 people.

Management Performance

Return On Equity-13.37
Return On Asset-0.6

Herantis Pharma Oyj Leadership Team

Elected by the shareholders, the Herantis Pharma's board of directors comprises two types of representatives: Herantis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Herantis. The board's role is to monitor Herantis Pharma's management team and ensure that shareholders' interests are well served. Herantis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Herantis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Henri Huttunen, Chief Scientific Officer
Sigrid Booms, Director of Clinical Development
Antti D, CEO COO
Jutta Poutanen, Chief Pharmaceutical Officer
Jani Koskinen, Project Manager
Outi MD, Chief Ofcer
Tone Kvale, Chief Officer

Herantis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Herantis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-13.37
Return On Asset-0.6
Current Valuation25.86 M
Shares Outstanding16.91 M
Shares Owned By Insiders31.52 %
Shares Owned By Institutions32.60 %
Price To Earning(7.20) X
Price To Book15.17 X
Gross Profit90 K
EBITDA(9.74 M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
BTCBitcoin
TRXTRON
BNBBinance Coin

Other Information on Investing in Herantis Stock

Herantis Pharma financial ratios help investors to determine whether Herantis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Herantis with respect to the benefits of owning Herantis Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY